The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study
Anesth Pain Med · 2013 · Vol. 2 · Issue 3 · 119-122
Academy Summary
The Effect of EMLA Cream on Patient-Controlled Analgesia with Remifentanil in ESWL Procedure: A Placebo-Controlled Randomized Study examined a clinically important component of shock wave lithotripsy, with particular relevance to SWL Pain Management.
The investigators used a Randomized Placebo-Controlled Trial in adults undergoing eswl. This design strengthens comparison between the treatment strategies studied, although the conclusions still remain tied to the lithotripter, protocol and eligibility criteria used.
A placebo-controlled randomized study evaluated whether topical EMLA can reduce remifentanil requirements or improve pain control during ESWL.
Pain control during SWL is part of treatment quality, not merely patient comfort.
Analgesia studies should be interpreted through both comfort and technical performance because pain-related movement can reduce effective stone targeting. A comfortable patient is more likely to remain still, breathe predictably and maintain stable stone alignment throughout treatment.
Published in 2013, the study should still be interpreted according to its specific lithotripter, patient selection and outcome definitions rather than assumed to represent every modern SWL system.
For the Lithotripsy Academy database, the paper is most useful when interpreted as part of the complete treatment pathway rather than as an isolated numerical rule. Patient selection determines the opportunity for success, while targeting, coupling, shock-wave rate, energy strategy and operator technique determine how effectively that opportunity is converted into fragmentation and clearance.
Continue Learning
Explore related clinical guidance and structured education.
Comments & Discussion0 comments
Discuss the publication's evidence, limitations and practical relevance. Please do not include identifiable patient information or individual medical advice.
No comments yet. Start the discussion.
Please log in to join the discussion.
